Is Charles River Laboratories International (CRL) Cheap After Its Medigen Vaccine Partnership?
Simply Wall Street
Charles River Laboratories International (CRL) has drawn attention due to its recent partnership with Medigen Vaccine Biologics for next-generation vaccine work, utilizing its biologics testing and Next-Generation Sequencing platforms. While the company has seen a strong share price surge recently (64.91% in 90 days, 76.50% in 1 year), its 5-year return is down 35.88%. The most followed narrative values CRL at $313.61 per share, suggesting it is 8.1% undervalued compared to its recent close of $
Read the full story
This is a short summary. The complete article is published by Simply Wall Street.
Headline and summary aggregated from public news feeds. For information only — not financial advice.